DK1486565T3 - Kombination af PDGF, KGF, IGF og IGFBP til sårheling - Google Patents

Kombination af PDGF, KGF, IGF og IGFBP til sårheling

Info

Publication number
DK1486565T3
DK1486565T3 DK04019502T DK04019502T DK1486565T3 DK 1486565 T3 DK1486565 T3 DK 1486565T3 DK 04019502 T DK04019502 T DK 04019502T DK 04019502 T DK04019502 T DK 04019502T DK 1486565 T3 DK1486565 T3 DK 1486565T3
Authority
DK
Denmark
Prior art keywords
pdgf
kgf
igf
combination
igfbp
Prior art date
Application number
DK04019502T
Other languages
English (en)
Inventor
Lewis T Williams
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of DK1486565T3 publication Critical patent/DK1486565T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04019502T 1995-10-11 1996-09-27 Kombination af PDGF, KGF, IGF og IGFBP til sårheling DK1486565T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US507595P 1995-10-11 1995-10-11
US2154096P 1996-07-11 1996-07-11
US71974296A 1996-09-25 1996-09-25
PCT/US1996/015623 WO1997013857A1 (en) 1995-10-11 1996-09-27 Combination pdgf, kgf, igf and igfbp for wound healing

Publications (1)

Publication Number Publication Date
DK1486565T3 true DK1486565T3 (da) 2008-03-10

Family

ID=27357798

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04019502T DK1486565T3 (da) 1995-10-11 1996-09-27 Kombination af PDGF, KGF, IGF og IGFBP til sårheling

Country Status (10)

Country Link
US (2) US6903078B1 (da)
EP (2) EP1486565B1 (da)
JP (2) JPH11513405A (da)
AT (1) ATE274056T1 (da)
AU (1) AU7248896A (da)
DE (2) DE69633194T2 (da)
DK (1) DK1486565T3 (da)
ES (2) ES2293137T3 (da)
PT (2) PT1486565E (da)
WO (1) WO1997013857A1 (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110590930A (zh) * 2018-06-13 2019-12-20 四川好医生攀西药业有限责任公司 美洲大蠊生长因子pdgf在制备损伤修复药物中的应用

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1486565B1 (en) 1995-10-11 2007-11-21 Novartis Vaccines and Diagnostics, Inc. Combination of PDGF, KGF, IGF, and IGFBP for wound healing
CA2268741C (en) * 1996-10-15 2007-04-24 Amgen Inc. Uses of keratinocyte growth factor-2
EP1452205B1 (en) * 1996-10-15 2007-11-28 Amgen Inc. Uses of keratinocyte growth factor-2
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
US6486133B1 (en) 1997-03-07 2002-11-26 The Wistar Institute Of Anatomy And Biology Methods for inducing localized vascular development and enhancing the repair of a wound in the mammamian dermis
US7217570B2 (en) 2001-08-23 2007-05-15 The Wistar Institute Of Anatomy And Biology Organotypic intestinal culture and methods of use thereof
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
US20030219402A1 (en) * 2002-02-14 2003-11-27 Rutter William J. Chimeric molecules for cleavage in a treated host
US20050224082A1 (en) * 2004-04-05 2005-10-13 Johnson Arthur A Method for forming occlusive barrier over ear canal and kit for providing same
US7473678B2 (en) * 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US8114841B2 (en) 2004-10-14 2012-02-14 Biomimetic Therapeutics, Inc. Maxillofacial bone augmentation using rhPDGF-BB and a biocompatible matrix
US20070004036A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for keratinocyte culture
US20070003541A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for therapeutics
US20070128685A1 (en) * 2005-07-01 2007-06-07 Rodolfo Faudoa Methods and compositions for cell culture
ES2427993T3 (es) 2006-02-09 2013-11-05 Biomimetic Therapeutics, Llc Composiciones y métodos para el tratamiento de hueso
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
CA2656278C (en) 2006-06-30 2016-02-09 Biomimetic Therapeutics, Inc. Compositions and methods for treating rotator cuff injuries
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
US8106008B2 (en) 2006-11-03 2012-01-31 Biomimetic Therapeutics, Inc. Compositions and methods for arthrodetic procedures
AU2007319811A1 (en) * 2006-11-15 2008-05-22 Coda Therapeutics, Inc. Improved methods and compositions for wound healing
US20080195476A1 (en) * 2007-02-09 2008-08-14 Marchese Michael A Abandonment remarketing system
EP2252690A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
CA2710386A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Improved medical devices
AU2008343840A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions
EP2259807B1 (en) * 2008-02-07 2013-04-24 Biomimetic Therapeutics, Inc. Compositions for distraction osteogenesis
KR101021197B1 (ko) * 2008-04-11 2011-03-11 (주)케어젠 성장인자―미미킹 펩타이드 및 그의 용도
KR20110067035A (ko) 2008-09-09 2011-06-20 바이오미메틱 세라퓨틱스, 인크. 건 및 인대 손상의 치료를 위한 혈소판-유래 성장 인자 조성물 및 방법
WO2010102266A1 (en) * 2009-03-05 2010-09-10 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods for the treatment of osteochondral defects
EP2454368A4 (en) 2009-07-17 2013-01-09 Aaron Thomas Tabor COMPOSITIONS AND METHOD FOR THE GENETIC MODIFICATION OF COSMETIC FUNCTION CELLS FOR IMPROVING THE COSMETIC APPEARANCE PICTURE
CN102811622A (zh) 2010-02-22 2012-12-05 生物模拟治疗公司 用于治疗腱病的血小板衍生生长因子组合物和方法
US10279007B2 (en) 2010-11-15 2019-05-07 Oxygenetix Institute, Inc. Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs
WO2015063613A2 (en) 2013-11-01 2015-05-07 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
CN107109410B (zh) 2014-08-22 2021-11-02 奥克兰联合服务有限公司 通道调节剂
MX2017004520A (es) 2014-10-14 2018-03-15 Lynch Samuel Composiciones para tratar heridas.

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486491T2 (de) 1983-04-25 2003-01-16 Chiron Corp., Emeryville Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren
US5187263A (en) 1984-10-12 1993-02-16 Zymogenetics, Inc. Expression of biologically active PDGE analogs in eucaryotic cells
US4801542A (en) * 1984-10-12 1989-01-31 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4766073A (en) * 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
EP0259632B1 (en) * 1986-08-13 1995-12-13 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
CA1322714C (en) 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
IE60517B1 (en) 1986-11-14 1994-07-27 Inst Molecular Biology Inc Wound healing and bone regeneration
US5019559A (en) 1986-11-14 1991-05-28 President And Fellows Of Harvard College Wound healing using PDGF and IGF-II
US4885163A (en) 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
ES2153816T3 (es) 1989-01-31 2001-03-16 Jeffrey S Rubin Adn que codifica un factor de crecimiento especifico contra celulas epiteliales.
US5035887A (en) 1989-09-07 1991-07-30 Institute Of Moelcular Biology, Inc. Wound healing composition of IL-1 and PDGF or IGF-1
US5149792A (en) * 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
JPH04224522A (ja) * 1990-04-27 1992-08-13 Merck & Co Inc 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法
DE69102651T2 (de) * 1990-07-23 1994-10-06 Zymogenetics, Inc., Seattle, Wash. Proteaseresistenter pdgf und dessen verwendungen.
EP0546074B1 (en) 1990-08-28 2001-11-14 Chiron Corporation Genetic material encoding igfbp-5
US5212074A (en) 1990-08-28 1993-05-18 Chiron Corporation Genetic material encoding new insulin-like growth factor binding protein igfbp-6
IE913034A1 (en) 1990-08-28 1992-03-11 Chiron Corp New insulin-like growth factor binding protein (igfbp-5)
EP0556344B1 (en) 1991-01-08 2003-08-13 Chiron Corporation New insulin-like growth factor binding protein
FI924778A0 (fi) * 1991-02-22 1992-10-21 Amgen Inc Anvaendning av gm-csf och g-csf foer foersnabbande av saorlaekning
EP0580752A4 (en) 1991-04-19 1994-08-24 Mannheim Gmbh Boehringer Human bone derived insulin like growth factor binding protein
HUT67319A (en) 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
IL105529A0 (en) * 1992-05-01 1993-08-18 Amgen Inc Collagen-containing sponges as drug delivery for proteins
US5407913A (en) 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
JPH08500827A (ja) * 1992-08-26 1996-01-30 セルトリックス ファーマシューティカルズ，インコーポレイテッド 異化症状および全身性組織創傷の全身的治療方法
CA2154078A1 (en) * 1993-01-29 1994-08-04 George N. Cox Wound healing composition
JP3578761B2 (ja) * 1993-03-26 2004-10-20 アムジエン・インコーポレーテツド 表皮ケラチン細胞成長因子の治療目的での使用
US5750365A (en) * 1993-05-28 1998-05-12 The Ohio State University Research Foundation Isolated nucleic acid encoding a newt acidic fibroblast growth factor (AFGF)
KR960703433A (ko) 1993-06-29 1996-08-17 로버트 피. 블랙버언 증가된 생물학적 활성을 갖는 끝이 잘린 케라틴세포성장인자(kgf) (a truncated keratinocyte growth factor(kgf) having increased biological activity)
US5624893A (en) 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
EP1486565B1 (en) 1995-10-11 2007-11-21 Novartis Vaccines and Diagnostics, Inc. Combination of PDGF, KGF, IGF, and IGFBP for wound healing

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110590930A (zh) * 2018-06-13 2019-12-20 四川好医生攀西药业有限责任公司 美洲大蠊生长因子pdgf在制备损伤修复药物中的应用
CN110590930B (zh) * 2018-06-13 2023-03-31 四川好医生攀西药业有限责任公司 美洲大蠊生长因子pdgf在制备损伤修复药物中的应用

Also Published As

Publication number Publication date
PT871730E (pt) 2004-11-30
US6903078B1 (en) 2005-06-07
JP2007182461A (ja) 2007-07-19
ES2293137T3 (es) 2008-03-16
DE69633194D1 (de) 2004-10-21
PT1486565E (pt) 2008-02-28
DE69633194T2 (de) 2005-09-08
DE69637332T2 (de) 2008-10-09
WO1997013857A1 (en) 1997-04-17
JPH11513405A (ja) 1999-11-16
HK1067382A1 (en) 2005-04-08
ES2224178T3 (es) 2005-03-01
EP0871730A1 (en) 1998-10-21
ATE274056T1 (de) 2004-09-15
EP1486565A1 (en) 2004-12-15
AU7248896A (en) 1997-04-30
EP1486565B1 (en) 2007-11-21
DE69637332D1 (de) 2008-01-03
US20050250695A1 (en) 2005-11-10
EP0871730B1 (en) 2004-08-18

Similar Documents

Publication Publication Date Title
DK1486565T3 (da) Kombination af PDGF, KGF, IGF og IGFBP til sårheling
DK0758904T3 (da) Fremgangsmåder og sammensætninger til behandling af glomerulonephritis
NO980255D0 (no) Antiparasittiske marcfortiner og paraherkvamider
ID21924A (id) Olanzapin dihidrat d
FI953926A7 (fi) Hormonin palautushoito
DK151687A (da) Aprotinin-homologe fremstillet ud fra en rekombinant vaert, fremgangsmaade, ekspressionsvektor og rekombinant vaert derfor og farmaceutisk anvendelse deraf
EP1005867A3 (en) Botulinum toxins for modulating cholinergic controlled secretions
FI99108B (fi) Menetelmä hissin ohjaamiseksi
KR970705926A (ko) 곤충방제를 위한 유화가능한 조성물(emusifiable composition for the control of insects)
NO964407D0 (no) Sprayemateriale og fremgangsmåte for spraying under anvendelse av materialet
DE69609256D1 (de) Sicheres aktualisierungsverfahren für eeprom
DE4397203T1 (de) Helligkeitssteuersystem für eine zahnärztliche Handstückbeleuchtung
BR9813996A (pt) 2-arilbenzo[b]tiofenos úteis para o tratamento de sìndrome da privação de estrogênio
FI970203A0 (fi) Pyridyylitioyhdisteet helikobakteerien torjumiseksi
DK1291018T3 (da) Phosphonatananaloger til mannose-6phosphat og deres anvendelse i behandlingen af sår og fibrotiske lidelser
DK207384A (da) Anvendelse af difunktionelle acrylsyre- og methacrylsyreestere til fremstilling af haerdelige knoglecementer
MY140504A (en) Statin-mmp inhibitor combinations
ATE180243T1 (de) Expansionsbindemittel
DE69735341D1 (de) Benzo(b)thiophenderivate, Zwischenprodukte, Zubereitungen und Verfahren
DK0832883T3 (da) Tetrahydrobenzo(a)fluorenforbindelser og fremgangsmåder til anvendelse
DK0871730T3 (da) Kombination af PDGF, KGF, IGF og IGFBP til sårheling
FR2711511B1 (fr) Prothèses métatarso-phalangiennes temporaires.
DK0832882T3 (da) Naphthofluorenforbindelser, mellemprodukter, præparater og fremgangsmåder
BR1100506A (pt) Composição para o tratamento de um ser humano sofrendo de um distúrbio intestinal.
KR940023930U (ko) 신발 골(last)